HQ Equita successfully concludes fundraising for HQ Equita V

HQ Capital

Bad Homburg, April 11 2019 – HQ Equita has successfully concluded fundraising for its fifth fund, HQ Equita V (“Fund V” or the “Fund”), with capital commitments totaling €308 million. With the Fund now closed, at a level comparable to its main predecessor fund, HQ Equita remains true with its strategic investment focus.

Established as a GmbH & Co. KG based in Bad Homburg, Germany, Fund V will focus on investments in small- and medium-sized enterprises (“SMEs”) in German-speaking Europe. The Fund’s limited partners include entrepreneurial families, foundations, and select institutional investors, consistent with HQ Equita’s historical investor base comprised of entrepreneurial capital. With investors from both European and non-European countries committing to the Fund, HQ Equita continues to expand its international network.

“Our strategy of developing partnerships to further advance and create value for German-speaking SMEs attracted great interest from investors. We will leverage our team’s deep experience and our broad network to support our portfolio companies’ growth and generate value for both the companies and our investors. With Fund V, we will continue to invest in SMEs, seek to expand our team and advance our strategic development even further,” said Christine Weiß, Partner and Managing Director at HQ Equita.

Since 2017, Fund V has already invested in four attractive companies. The portfolio includes WELL PLUS TRADE (2017), The Packaging Group – consisting of FAWEMA and HDG – (2018), r2p (2018), and EBERTLANG (2019). WELL PLUS TRADE is a specialist developer of protein-based sports nutrition. The Packaging Group is a leading manufacturer of packaging machines. r2p is an international provider of digital systems for public transportation. And EBERTLANG is a leading value-added distributor of infrastructure software for SMEs in German-speaking Europe.

With these four investments, HQ Equita continues to pursue its nearly three-decade long focus on investing in highly specialized small- and medium-sized “hidden champions” in Germany, Austria and Switzerland. By investing in companies with revenues ranging between €20 million and €150 million, HQ Equita is able to provide sustainable growth capital, enact succession planning solutions, and provide the network necessary to develop corporate structures and internationalize the businesses.

“HQ Equita has continued to enhance its profile over the years and remains a trusted partner for growth capital and succession planning solutions for SMEs in German-speaking Europe. With the successful closing of Fund V and the initiation of the generational management change, the foundation for long-term stability and continuity at HQ Equita is firmly in place,” said Dr. Bernd Türk, Managing Director and Chairman of the Executive Committee of HQ Capital.

After three successful investments in the last 12 months, HQ Equita will continue to strategically deploy capital in attractive portfolio companies in the German-speaking DACH region.

Categories: News

Tags:

HQ Capital Real Estate’s Investment and Sales Activity Nearly $1 Billion in 2018

HQ Capital

[New York, NY / Bad Homburg, 9 April 2019]. HQ Capital, a leading independent manager of alternative investments, announces $840 million of real estate activity in 2018. Over the past year, the firm invested in eight multifamily investments throughout the U.S. in Arizona, California, Colorado, Georgia, Massachusetts, Tennessee and Texas, representing nearly 1,800 units with total project costs of $410 million.

 

“We experienced strong rental apartment demand, driven by healthy job gains last year,” said Justin Sorem, Vice President of Real Estate Asset Management at HQ Capital. “In the coming year, we expect to see this absorption continue, which will position our projects for further successful sales to apartment buyers.”

Beyond its investments, HQ Capital sold 11 residential and commercial properties valued at approximately $430 million and representing more than 2,300 apartment units and 360,000 square feet of commercial space throughout the U.S. The properties, which were sold to various institutional and private investors, were located in Growth markets primarily in the Southern and Western regions of the U.S.

“In 2018, we continued to successfully invest in and sell U.S. multifamily properties,” said Jeremy Katz, Co-Head of Real Estate at HQ Capital. “We are benefiting from a highly active sales market in which institutional investors seeking nonvolatile current returns are attracted to the core product we are delivering.”

In addition to its investment and sales activity, HQ Capital added a 68,000-square foot office building in Washington, D.C. to its third-party asset management portfolio.

The company expects to continue its current level of business activity in 2019.

Categories: News

Tags:

StageBio and Tox Path Specialists Merge

Two market leaders join forces to meet the growing demand for high-quality histopathology and neuropathology services in the preclinical therapeutics market

JACKSON, VA and FREDERICK, MD (USA) – April 10, 2019 – StageBio has merged with Tox Path Specialists, LLC (TPS) to create the leading provider of research and preclinical histology, pathology, specialized neuropathology and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the merger of Histo-Scientific Research Laboratories (HSRL) and Vet Path Services (VPS) and is a portfolio company of Ampersand Capital Partners.

“We are very excited to merge operations with Dr. Mark Butt and his team at Tox Path Specialists as we continue to broaden our service offerings to both new and existing clients,” said Tom Galati, StageBio CEO. “It is our intent to position StageBio as the most capable histopathology company in the industry”.

Dr. Mark Butt, Founder & CEO of Tox Path Specialists, commented, “StageBio and TPS are a natural fit. The broad spectrum of histopathology services of StageBio coupled with our specialty neuropathology capabilities are a great match and will further streamline the research process for our clients”. The merger adds laboratory space in Frederick, MD, and more importantly adds staff with vast experience in specialty neuropathology techniques to complement the StageBio team based in Virginia, Ohio and Massachusetts. The combined business has over 20 board-certified pathologists and a total employee base of over 100.



About StageBio

StageBio is the leading provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries. We provide our customers with a fully-integrated breadth of histopathology services, including tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to FDA approval, detailed pathology reporting for GLP studies, medical device pathology and immunohistochemistry. We operate four state-of-the-art sites in the US, with substantial continued investment in our facility and technology infrastructures to meet the growing demand for high-quality histopathology services. With more than 20 board-certified veterinary pathologists and over 50 laboratory technicians on staff, we are ideally positioned to deliver on our unified commitment to quality, scientific integrity and customer service excellence. Additional information about StageBio is available at www.stagebio.com.

About Tox Path Specialists

Founded in 2006, TPS is one of the leading neuropathology laboratories in North America. Founded and led by Dr. Mark Butt, TPS specializes in comprehensive evaluations of the central and peripheral nervous system. TPS is a full-service GLP histopathology laboratory, offering expertise in histology, pathology immunohistochemistry, image analysis and stereology. Its staff consists of 2 board-certified (ACVP) veterinary pathologists, 6 highly-trained histology technicians as well as dedicated Quality Control (QC) and Quality Assurance (QA) units, all of whom are committed to quality work, excellent customer service and meeting demanding timelines. Additional information about TPS is available at www.toxpath.net.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information about Ampersand is available at ampersandcapital.com.

For further information contact:

Sam Jeffrey
Director of Corporate Development
info@stagebio.com

Categories: News

Tags:

Hengli Investments Holding Group and Gaw Capital Partners Close Acquisition of Cityplaza Three & Four in Hong Kong

Gaw Capital

April 11, 2019, Hong Kong – Hengli Investments Holding (Group) Ltd. (“Hengli Group”) and real estate private equity firm Gaw Capital Partners, through a fund under its management, today closed the acquisition of portions of Cityplaza Three (including 10 high zone office floors and commercial areas) and Cityplaza Four from Swire Properties. The partners closed the acquisition of the two office towers for HK$15 billion, amounting to an average price of around HK$19,350 per sq. ft.

Located in the growing business center of Taikoo Shing in Hong Kong’s Eastern District, the two 22-storey Grade-A office towers have a combined GFA of around 775,000 sq. ft. and enjoy views over the Victoria Harbor with direct walkways connecting the buildings to Tai Koo MTR station and Cityplaza shopping mall. With the recent opening of the Central-Wan Chai Bypass, the towers also have quick and convenient access to the Central business district.

Chang Wei Chen, Chairman of Hengli Investments Holding (Group) Ltd., said, “Record-high rents in traditional business areas have created demand for more cost-effective and spacious Grade-A office buildings in emerging commercial districts, creating huge potential for areas like Taikoo Shing. Working closely with Gaw Capital’s team, we look forward to adding strategic value to Cityplaza Three and Four through property enhancement work, leveraging the towers’ attractive location in the fast-growing Eastern District to capture this new wave of tenants. This investment is one of the long-holding properties of our Group in Hong Kong, which provides continuous stable rental returns.”

Mr. Chen, possessing over 30 years of experience in investment, industrial and commercial sectors and real estate development, is the key decision maker on strategic development for Hengli Group. Mr. Chen is currently the second-largest shareholder of Wanda Hotel. Wanda Hotel is principally engaged in property development, property letting, property management and investment holding activities.

Kenneth Gaw, President and Managing Principal of Gaw Capital Partners, said, “We are delighted to be partnering with Hengli Group to purchase portions of Cityplaza Three (including 10 high zone office floors and commercial areas) and Cityplaza Four and to reposition them into attractive office space that appeals to the new wave of businesses moving into Taikoo district. Riding on the properties’ promising location, we will deploy a creative approach to asset management that strengthens the buildings’ pull factors and makes them a key destination for firms that are looking to relocate to the Eastern District.”

Gaw Capital has over 13 years of experience investing in and/or turning around commercial properties in Greater China, including Hong Kong. The firm successfully transformed and repositioned properties such as 133 Wai Yip Street in Hong Kong, a former 12-storey industrial building turned creative office space; and Sky Bridge HQ, a mixed-use project located in the heart of Linkong Economic Park in Shanghai. In recent years, the firm also purchased 29 local Hong Kong shopping malls from Link REIT, which it intends to reposition and revitalize into attractive hubs of community life.

Categories: News

Tags:

The Carlyle Group Agrees to Sell vwd, a Provider of Innovative Software Solutions to the Investment Industry, to Infront

Carlyle

Carlyle Supported vwd‘s Development to Become a Significant European Information and Technology Solutions Provider

London/Frankfurt – Global investment firm The Carlyle Group (NASDAQ: CG) announced today that it has agreed to sell vwd Vereinigte Wirtschaftsdienste GmbH (vwd), a European provider of software solutions for investment professionals, to Infront ASA (Infront). Infront is a European market leader for real-time market data, trading, news and analytics applications based in Oslo, Norway. The transaction is subject to approval from the relevant antitrust and financial regulatory authorities.

Headquartered in Frankfurt, Germany, vwd is a provider of software for the investment industry. With its intuitive solutions on a modular technology platform, vwd empowers wealth management and investment professionals to make smarter, more efficient and regulatory-compliant investment decisions.

Carlyle invested in vwd in 2012 through Carlyle Europe Technology Partners II (CETP II), a pan-European small & mid-market buyout fund dedicated to investing in technology-focused B2B companies with annual revenues of €15 to €150 million. The CETP team has extensive global experience in the management of technology companies, as well as in German-speaking countries.

Infront was founded by CEO Kristian Nesbak and CIO Morten Lindeman in 1998 and is listed on the Oslo stock exchange. It is a leading market data and trading solution provider in the Nordics with customers in more than 50 countries.

In this new strategic partnership, vwd’s comprehensive offering covering data & feed, portfolio & advisory, regulatory & calculation and publication & distribution solutions will be complemented by Infront’s best-in-class market data and trading solutions. vwd will therefore be able to continue pursuing its unified platform product strategy with Infront adding a highly sophisticated front-office trading product suite. Both vwd and Infront customers will benefit from the two companies combining their sector-defining capabilities across regulation, private wealth management and market data.       

Kristian Nesbak, Infront CEO, commented: “The merger of vwd and Infront will allow us to create one of the largest and most relevant players in Europe. Our highly complementary product solutions and core markets will enable us to pursue an ambitious common growth plan.”   

Shiva Ramabadran, vwd CEO said: “Joining forces with Infront will allow us to be an even stronger partner for our customers who will greatly benefit from a more diversified solutions offering. Due to vwd’s significant contributions to the new combined entity, we will be able to continue fulfilling all customer requests and be on the ground in our core markets.”   

Thorsten Dippel, Managing Director of the Carlyle Europe Technology Partners (CETP) team said: “Infront is an ideal partner for vwd. We are delighted to see that Infront will support and accelerate vwd’s successful strategic development. We would like to thank vwd’s management team for their trust and cooperation during our successful partnership and wish vwd and Infront continued future success.” 

vwd’s management team will be fully integrated into the new joint executive team and will remain as ongoing contacts for all vwd customers and business partners.

* * * * *

Media contacts:

Catherine Armstrong
+44 20 7894 1632, catherine.armstrong@carlyle.com

Katharina Gebsattel
T +49 172 718 68 57, katharina.gebsattel@vub.de

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $216 billion of assets under management as of December 31, 2018, Carlyle’s purpose is to invest wisely and create value on behalf of our investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,650 people in 31 offices across six continents.

Web: www.carlyle.com
Videos: www.youtube.com/onecarlyle
Tweets: www.twitter.com/onecarlyle
Podcasts: www.carlyle.com/about-carlyle/market-commentary

About Infront

Infront provides a unique combination of global market data, news, analytics and trading tools. With over 20 years of product development driven by our clients’ business needs, the Infront Professional Terminal is the most user-friendly and flexible terminal in the financial market. We help buy-side and sell-side institutions grow their businesses, reduce costs, adapt to fast changing market requirements and work more effectively with ever-increasing amounts of information. Over 40,000 professional subscribers worldwide rely on Infront’s services. Infront is listed on the Oslo Stock Exchange and has offices in eight countries across Europe and South Africa.

About vwd

vwd is a leading software provider for the investment industry, With its intuitive solutions on a modular technology platform, vwd empowers wealth management and investment professionals to make smarter, more efficient and regulatory compliant investment decisions. Headquartered in Frankfurt, vwd has offices in 6 countries where it serves more than 2,400 businesses with data, services and software solutions.

Categories: News

Tags:

Bregal Partners announces closing of its second Fund with $650 million of commitments

Bregal Partners

New York, NY, April 11, 2019 – Bregal Partners today announced the closing of its second fund, Bregal Partners II LP. The fund closed on $650 million of capital commitments sourced from its current limited partners. The $650 million brings Bregal Partners to a total of $1.25 billion in committed capital under management.

“Our team is proud and appreciative of the support we’ve received from our limited partners,” said Scott Perekslis, Co-Founder and Managing Partner of Bregal Partners. “We sincerely value these relationships and the confidence our investors have shown in our team and investment strategy.”

Charles Yoon, Managing Partner at Bregal Partners, added, “We are long-term partners to entrepreneurs, founders, and management teams, working with them to build and scale their businesses. Fund II is off to a great start having already invested in three founder-owned platforms in the consumer, food and retail industries.”

About Bregal Partners

Bregal Partners is a leading middle-market private equity firm with $1.25 billion in total committed capital. Founded in 2012, the firm specializes in three core verticals: consumer and multi-unit, food and beverage, and business services. The firm invests in primarily founder-owned companies within its target industries that generate $5 to $75 million or more of EBITDA. Bregal Partners is committed to promoting corporate social responsibility in all aspects of its business. For more information, please visit www.bregalpartners.com.

About Bregal Investments

Bregal Investments is a global private equity investment firm with investment teams based in New York, London, Munich and Dallas, managing commitments on behalf of several limited partners. Bregal Investments is an operating company of COFRA, a privately held group of companies headquartered in Europe which also include a global fashion retail business (C&A) and real estate business (Redevco).

Bregal Investments’ investment teams specialize in private equity buy-outs, special situations, credit, energy and private equity fund investing. The firm focuses on transforming and growing businesses for future success, with its funds focusing on longer-term value creation. Bregal was founded in 2002 and has grown extensively since then, with approximately $16 billion invested to date. For more information, please visit www.bregal.com.

Contact:
Antonia Schwartz
Director, Head of Capital Development
(212) 704-3014
antonia.schwartz@bregal.com

Categories: News

Tags:

Genstar Capital Announces Acquisition of Ohio Transmission Corporation in Partnership with Management

OTC to Benefit from Accelerating Industry Demand for Factory Automation


SAN FRANCISCO, April 9, 2019—Genstar Capital, a leading private equity firm focused on investments in targeted segments of the industrial technology, healthcare, software, and financial services industries, today announced the acquisition of Ohio Transmission Corporation (OTC), an industrial automation equipment distributor and technical service provider.

Ohio Transmission Corporation is a leading technical distributor of highly engineered products including motion control, pumps, finishing products, robotics, motors and air compressors.  OTC serves over 13,000 customers across diverse end-markets, providing highly technical sales consultation and aftermarket repair and services. Key end markets include transportation, industrial machinery, metals, chemicals, and food & beverage among others.  Founded in 1963 and headquartered in Columbus, Ohio, OTC’s geographic footprint includes 38 branch locations in 17 states.

Rob Rutledge, Managing Director at Genstar said, “OTC operates at a pivotal point in the manufacturing sector, benefiting suppliers looking to partner with distributors with broader product and service capabilities and customers who are increasingly relying on distributors with strong technical resources.  The company provides a leading brand portfolio of highly technical products, value added services and specialized solutions with a proven track record of adding new product categories.  We look forward to supporting management’s strategy of product and geographic expansion organically as well as through strategic acquisitions to better serve OTC’s customers.”

Philip Derrow, Chief Executive Officer of OTC, said, “My father founded a company that for nearly 60 years has operated with an established culture and values rooted in integrity, achievement, and growth.  Genstar has direct experience working with industrial technology companies like ours and we look forward to working with their investment and operating partners to capitalize on numerous growth opportunities to broaden our geographic reach and enhance our technical solutions offerings to better serve our customers and suppliers and create opportunities for our associates.”

OTC has been a successful integrator, completing 16 successful acquisitions since 2010, and maintains a robust pipeline of actionable platform enhancing opportunities.

Weil, Gotshal & Manges LLP acted as legal counsel to Genstar Capital in the acquisition.

About Genstar Capital

Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high quality companies for over 30 years.  Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $17 billion of assets under management and targets investments focused on targeted segments of the industrial technology, healthcare, software, and financial services industries.

###

MEDIA INQUIRIES:

Contact: Chris Tofalli
Chris Tofalli Public Relations
914-834-4333

 

Categories: News

Tags:

Ratos sells property to Swedish state

Ratos

As previously announced, Ratos has been in negotiations with the National Property Board of Sweden regarding a possible transfer of ownership of its Stockholm Lejonet 4 property to the Swedish state. Following these negotiations, an agreement has now been reached for the Swedish state to purchase the property. The agreement is conditional on the National Property Board receiving authorisation to complete the agreement from the Swedish government, upon approval from parliament, by 19 July 2019 at the latest.

Ratos will receive 550 MSEK in conjunction with the sale. The consolidated book value for the property at 31 December 2018 was 56 MSEK.

“The Stockholm Lejonet 4 property was acquired by Söderberg & Haak in 1938 and by Ratos AB (publ) in 1980. The security requirements in the area surrounding the property have gradually increased, resulting in a number of restrictions and obstacles in terms of how the property can be used, including entry and exit restrictions. Allowing the National Property Board to take over the property is therefore a logical alternative”, says Jonas Wiström, CEO of Ratos.

Ratos has the option to remain in the property until the end of 2021.

For further information, please contact:
Jonas Wiström, CEO, Ratos, +46 8 700 17 00
Helene Gustafsson, Head of IR and Press, Ratos, +46 70 868 40 50

About Ratos:
Ratos owns and develops unlisted medium-sized companies in the Nordic countries. Our goal as an active owner is to contribute to long-term and sustainable operational development in the companies we invest in and to make value-generating transactions. Ratos’s portfolio consists of 12 medium-sized Nordic companies and the largest segments in terms of sales are Construction, Industrials and Consumer goods/Commerce. Ratos is listed on Nasdaq Stockholm and has approximately 12,300 employees.

Categories: News

Tags:

ICG Europe VII, in partnership with Mérieux Equity Partners, buys DOC Generici from CVC Fund VI

Doc Generici one of Italy’s largest independent generic pharmaceutical companies

Intermediate Capital Group’s Europe VII Fund is pleased to announce it has, in partnership with Mérieux Equity Partners and DOC Generici’s management team, agreed to invest in Doc Generici, one of Italy’s largest independent generic pharmaceutical companies – subject to antitrust approval.

DOC Generici provides drugs for the treatment of common medical conditions with a broad product portfolio and a strong presence in areas including cardiovascular, gastrointestinal/metabolism and neurological treatments. The company operates an asset-light model and benefits from a consolidated network of suppliers.

This is the seventh deal for the Europe VII fund, which provides long term financing for growing private companies across Europe. The fund closed with €4.5bn of commitments in November 2018.

Luigi Bartone, Head of Italian Subordinated Debt & Equity Investments, said: “DOC Generici exhibits the classic characteristics we look for in an investment. The company is well established, highly cash generative, and led by a best-in class, committed management team. It benefits from a resilient and growing market driven by the ongoing penetration of generics in the Italian pharmaceutical market. We believe there are significant opportunities to continue to grow the business, and ICG resources and global networks will support management’s and Mérieux’s vision.”

Benoît Durteste, Chief Executive and Chief Investment Officer of ICG, said: “This is a significant deal for Europe Fund VII and a milestone deal for ICG in Italy. It demonstrates how our local teams continue to find attractive investment opportunities across Europe which have the potential to produce strong growth and enable us to deliver on behalf of our fund investors.”

Benoît Chastaing, Senior Partner at Merieux Equity Partners, said: “We are pleased to collaborate with ICG and DOC Generici management team, to invest in one of the leaders within the Italian Generic market. DOC Generici clearly improves access for patients to high-value medicine, this is in line with Mérieux Participations 3 investment strategy, recently set-up to support fast-growing companies within the healthcare and nutrition markets. This transaction also constitutes the first landmark investment of Mérieux Equity Partners in Italy. We will share our expertise and industrial network with Doc Generici and ICG over the coming years.”

Giorgio De Palma, Senior Managing Director at CVC said: “DOC Generici is a high-quality business with strong organic growth and high cash generation led by an outstanding management team. The launch of two new branded franchises in Ophthalmology and Cardiovascular Medicine have further strengthened DOC’s market position over the last three years. We thank Gualtiero Pasquarelli and the rest of the management team for the ongoing success of DOC Generici and wish them all the best for the future”.

Gualtiero Pasquarelli, CEO at DOC Generici, said: “We would like to thank CVC for their support, which has been instrumental in the acceleration of DOC’s growth strategy. DOC Generici has delivered very solid results in terms of sales and EBITDA, outperforming the reference market, and has significant potential for further growth. We now look forward to working with ICG and Mérieux in the next stage of our development.”

Barclays acted as sole financial adviser for ICG, Studio Gattai Minoli Agostinelli and Latham & Watkins as legal advisor. White&Case acted as legal advisor to Mérieux Equity Partners. Legance Studio Legale Associato acted as legal advisor and Studio Facchini Rossi & Soci acted as tax advisor for CVC.

Categories: News

Tags:

Everstone Group to acquire controlling stake in Sahyadri Hospitals

Everstone

Mumbai, April 07, 2019 – The Everstone Group(Everstone), has signed an agreement to acquire a controlling stake in Sahyadri Hospitals Limited(Sahyadri), the largest hospital chain in Maharashtra. The combination of primary and secondary capital outlay is expected to increase the bed-count significantly in next five years.

Founded in 1994, Pune headquartered Sahyadri Hospitals currently operates 5 tertiary care and 3 secondary care hospitals with 750 beds across Pune (Deccan Gymkhana, Nagar Road, Kothrud, Bibwewadi, Kasba Peth and Hadapsar), Nashik and Karad areas. Sahyadri has more than 1000 clinicians along with 2300 supporting staff providing latest medical services.

Sameer Sain, CEO, Everstone Group, said, “Sahyadri Hospitals is a reputed name for quality healthcare and will act as the anchor asset of our healthcare delivery platform. Everstone will leverage its’ significant healthcare expertise and experience to grow the overall business. We look forward to working closely with our partners and stakeholders.”

Commenting on the investment, Dr. Charudutt Apte, Founder, Chairman and MD, Sahyadri Hospitals said, “We are excited about this partnership and the value Everstone Group brings. Sahyadri Hospitals looks forward to the next phase of growth with the support of the experienced team at Everstone.”

According to industry estimates, private secondary and tertiary healthcare delivery in India is expected to grow from USD 42 bn in 2018 to USD 65 bn by 2022 at a CAGR of ~12%. This investment will help Sahyadri to cement its position as the leading healthcare chain in Maharashtra.

Everstone is one of the largest India and South East Asia focused healthcare investor specializing in rolling up assets within their platforms. In 2015, Everstone successfully exited Global Hospitals, a large multi-specialty tertiary hospital chain, generating strong returns. Everstone’s healthcare portfolio includes controlling stakes in domestic pharma distribution platform, Ascent Health; South East Asia based diagnostic device platform Everlife and an investment in one of the largest nutraceutical ingredient business, OmniActive. Everstone recently announced its successful exit from Rubicon Research (Rubicon) generating returns of 4.5x.

About Everstone Group
Everstone is a premier investment group focused on India and South East Asia, with assets in excess of US$5 billion across private equity, real estate, green infrastructure and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India (Mumbai, Delhi, Bangalore), London, New York and Mauritius, comprising best-of-breed investing, operations and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com
LinkedIn

About Sahyadri Hospitals
Sahyadri Hospitals is the largest chain of hospitals in Maharashtra with 8 hospitals across three cities of Pune, Nashik and Karad. The hospital chain has over 900 Beds, 1,200 Clinicians and 2,300 Support Staff providing round the clock healthcare.
To know more: www.sahyadrihospital.com

Categories: News

Tags: